KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5136.37M
Enterprise Value 3120.38M
Trailing P/E N/A
Forward P/E 1-1.83
PEG Ratio (5 yr expected) 1-0.05
Price/Sales (ttm)39.61
Price/Book (mrq)2.23
Enterprise Value/Revenue 334.96
Enterprise Value/EBITDA 6-1.42

Trading Information

Stock Price History

Beta (3Y Monthly) 1.99
52-Week Change 3-68.19%
S&P500 52-Week Change 31.52%
52 Week High 314.4490
52 Week Low 33.8100
50-Day Moving Average 35.4549
200-Day Moving Average 36.6862

Share Statistics

Avg Vol (3 month) 3276.33k
Avg Vol (10 day) 3378.29k
Shares Outstanding 533.88M
Float 20.43M
% Held by Insiders 14.25%
% Held by Institutions 181.36%
Shares Short (Jul 31, 2019) 41.97M
Short Ratio (Jul 31, 2019) 410.61
Short % of Float (Jul 31, 2019) 49.08%
Short % of Shares Outstanding (Jul 31, 2019) 45.80%
Shares Short (prior month Jun 28, 2019) 41.76M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,484.00%

Management Effectiveness

Return on Assets (ttm)-38.96%
Return on Equity (ttm)-139.42%

Income Statement

Revenue (ttm)3.44M
Revenue Per Share (ttm)0.11
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -84.96M
Net Income Avi to Common (ttm)-90.03M
Diluted EPS (ttm)-2.8660
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)118.01M
Total Cash Per Share (mrq)3.47
Total Debt (mrq)101.67M
Total Debt/Equity (mrq)166.50
Current Ratio (mrq)7.50
Book Value Per Share (mrq)1.80

Cash Flow Statement

Operating Cash Flow (ttm)-83.8M
Levered Free Cash Flow (ttm)-53.72M